Developer docs
API playgroundTry for free, no card

Search company profiles

Biofarm

Full company profile

uuid002hapf

Namestring
Biofarm
Legal namestring
Biofarm S.A.
Websiteurl
biofarm.ro
Company typeenum
Public
Founded yearint
1921
Descriptiontext

Biofarm S.A. is a Romanian pharmaceutical manufacturer, established in 1921 and headquartered in Bucharest, that produces medicines and food supplements. The company is listed on the Bucharest Stock Exchange under the ticker BVB:BIO and operates with between 251 and 500 employees. Its product portfolio spans registered pharmaceutical medicines and consumer health food supplements, sold through Romania's pharmacy, hospital, and distribution channels typical of a domestic generics producer.

The business is owned in part by Longshield Investment Group SA and Lion Capital S.A., alongside other public shareholders. On May 6, 2026, Polpharma SA Pharmaceutical Works — a larger European generics operator — launched a voluntary tender offer to acquire Biofarm S.A. from these shareholders for RON 1.4 billion, equating to RON 1.379 per share in cash, a premium of roughly 15 percent over the prevailing market price. The transaction is subject to approval by the Romanian Financial Supervisory Authority, and a special dividend of RON 0.140263 per share is intended to be distributed to shareholders ahead of the tender offer launch. Biofarm's shares rose 2.9 percent on May 7, 2026 following the announcement.

Day-to-day operations are led by Catalin Vicol, who serves as Chief Executive Officer, General Manager, and Board Member. On completion of the Polpharma transaction, Biofarm would become a subsidiary of Polpharma SA Pharmaceutical Works, transitioning from public to private ownership under a larger strategic operator in the European generics market.

Short descriptiontext

Biofarm S.A. is a Romanian pharmaceutical manufacturer, founded in 1921 and listed on the Bucharest Stock Exchange (BVB:BIO), producing medicines and food supplements for the Romanian domestic market and currently subject to a voluntary tender offer from Polpharma SA Pharmaceutical Works.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersBucharest, Romania
HQ citystring
Bucharest
HQ countrystring
Romania
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
pharmaceutical manufacturing, food supplements, OTC medicines, consumer healthcare, Romanian pharmaceuticals
Industry1 code
PRIMARYEUAAAIAK
Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives
Energy, Utilities & Environment/Bioenergy, Natural Gas & Biomass/Biorefining & Bio-based Chemicals (Co-products, Bioproducts)
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Pharmaceutical Manufacturing
Social media profiles1 record
Cost components5 values
Operations, Supply Chain, Personnel, Marketing or Sales, Technology or R&D
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Biofarm is a Romanian pharmaceutical manufacturer founded in 1921 that produces and sells medicines and food supplements. The company manufactures over-the-counter (OTC) medicines and dietary supplements through its own production facilities in Bucharest, distributing its products through pharmacies and retail drug stores in Romania and surrounding markets.

Differentiator
Functional benefit
Problem solved
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

European-focused generic and consumer healthcare company; comparable to Biofarm as a generics-plus-supplements business, though operating at materially greater scale across multiple European markets.

TypeDirect peer
Description

Slovenian generic pharmaceutical producer with an established CEE and Eastern European distribution network; competes with Biofarm in similar generic and OTC categories across overlapping markets.

TypeBroad incumbent
Description

Largest Polish pharmaceutical manufacturer and the announced acquirer of Biofarm; comparable as a broad CEE generics and OTC player with significantly greater scale, product breadth, and international reach.

TypeDirect peer
Description

US-headquartered with significant Central and Eastern European generic pharmaceutical operations; directly comparable to Biofarm in generics portfolio and CEE distribution channels.

5Terapia (Sun Pharma Romania)
TypeDirect peer
Description

Romanian generic and OTC pharmaceutical operation of Sun Pharma, directly competing with Biofarm in the domestic generics and supplements market.

6Fiterman Pharma
TypeRegional player
Description

Romanian pharmaceutical and dietary supplement manufacturer with overlapping product categories (OTC and supplements); comparable as a same-geography peer focused on Romanian retail and pharmacy channels.

TypeDirect peer
Description

Hungary-based branded and generic pharmaceutical manufacturer with a similar CEE footprint and product breadth, comparable to Biofarm in therapeutic-area coverage and Central European commercial model.

TypeRegional player
Description

German-based mid-sized pharmaceutical company with strong CEE commercial presence in generics and supplements, comparable to Biofarm in product positioning and Eastern European go-to-market focus.

TypeDirect peer
Description

Pan-European generic and OTC pharmaceutical manufacturer headquartered in Prague with strong CEE presence, directly comparable to Biofarm in product mix, generic-and-supplement positioning, and regional distribution model.

TypeDirect peer
Description

Romanian pharmaceutical manufacturer producing generics, OTC, and supplements; directly comparable to Biofarm as a same-country peer with overlapping product categories and channel mix.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Biofarm

Pharmaceutical Manufacturingbiofarm.ro

Biofarm S.A. is a Romanian pharmaceutical manufacturer, founded in 1921 and listed on the Bucharest Stock Exchange (BVB:BIO), producing medicines and food supplements for the Romanian domestic market and currently subject to a voluntary tender offer from Polpharma SA Pharmaceutical Works.

What Biofarm does

Biofarm S.A. is a Romanian pharmaceutical manufacturer, established in 1921 and headquartered in Bucharest, that produces medicines and food supplements. The company is listed on the Bucharest Stock Exchange under the ticker BVB:BIO and operates with between 251 and 500 employees. Its product portfolio spans registered pharmaceutical medicines and consumer health food supplements, sold through Romania's pharmacy, hospital, and distribution channels typical of a domestic generics producer.

The business is owned in part by Longshield Investment Group SA and Lion Capital S.A., alongside other public shareholders. On May 6, 2026, Polpharma SA Pharmaceutical Works — a larger European generics operator — launched a voluntary tender offer to acquire Biofarm S.A. from these shareholders for RON 1.4 billion, equating to RON 1.379 per share in cash, a premium of roughly 15 percent over the prevailing market price. The transaction is subject to approval by the Romanian Financial Supervisory Authority, and a special dividend of RON 0.140263 per share is intended to be distributed to shareholders ahead of the tender offer launch. Biofarm's shares rose 2.9 percent on May 7, 2026 following the announcement.

Day-to-day operations are led by Catalin Vicol, who serves as Chief Executive Officer, General Manager, and Board Member. On completion of the Polpharma transaction, Biofarm would become a subsidiary of Polpharma SA Pharmaceutical Works, transitioning from public to private ownership under a larger strategic operator in the European generics market.

Biofarm firmographics

Firmographics
Name
Biofarm
Legal name
Biofarm S.A.
Website
https://biofarm.ro
Company type
Public
Founded year
1921
Operating status
Operating
Headcount range
251–500 employees
Short description
Biofarm S.A. is a Romanian pharmaceutical manufacturer, founded in 1921 and listed on the Bucharest Stock Exchange (BVB:BIO), producing medicines and food supplements for the Romanian domestic market and currently subject to a voluntary tender offer from Polpharma SA Pharmaceutical Works.
Ownership category
akta.pro rank

Biofarm industry classification

Industry
Product category
Pharmaceutical Manufacturing
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYEUAAAIAK
Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives
Energy, Utilities & Environment/Bioenergy, Natural Gas & Biomass/Biorefining & Bio-based Chemicals (Co-products, Bioproducts)

Keywords

  • Pharmaceutical manufacturing
  • Food supplements
  • OTC medicines
  • Consumer healthcare
  • Romanian pharmaceuticals

Where Biofarm is headquartered

Location

Headquarters

HQ city
Bucharest
HQ country
Romania
HQ region
Europe

Markets served

Biofarm business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Supply Chain, Personnel, Marketing or Sales, Technology or R&D

Biofarm product offering

Product offering

Core offering

Biofarm is a Romanian pharmaceutical manufacturer founded in 1921 that produces and sells medicines and food supplements. The company manufactures over-the-counter (OTC) medicines and dietary supplements through its own production facilities in Bucharest, distributing its products through pharmacies and retail drug stores in Romania and surrounding markets.

Differentiator

Problem solved

Functional benefit

Companies that use Biofarm

Customer profile

Ideal customer profiles2 records

Biofarm technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Biofarm partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves3 records

Expansion highlights2 records

Biofarm competitors and assessment

Company assessment

Broad incumbents

  • STADA Arzneimittel: European-focused generic and consumer healthcare company; comparable to Biofarm as a generics-plus-supplements business, though operating at materially greater scale across multiple European markets.
  • Polpharma: Largest Polish pharmaceutical manufacturer and the announced acquirer of Biofarm; comparable as a broad CEE generics and OTC player with significantly greater scale, product breadth, and international reach.

Direct peers

  • KRKA: Slovenian generic pharmaceutical producer with an established CEE and Eastern European distribution network; competes with Biofarm in similar generic and OTC categories across overlapping markets.
  • Alvogen: US-headquartered with significant Central and Eastern European generic pharmaceutical operations; directly comparable to Biofarm in generics portfolio and CEE distribution channels.
  • Terapia (Sun Pharma Romania): Romanian generic and OTC pharmaceutical operation of Sun Pharma, directly competing with Biofarm in the domestic generics and supplements market.
  • Gedeon Richter: Hungary-based branded and generic pharmaceutical manufacturer with a similar CEE footprint and product breadth, comparable to Biofarm in therapeutic-area coverage and Central European commercial model.
  • Zentiva: Pan-European generic and OTC pharmaceutical manufacturer headquartered in Prague with strong CEE presence, directly comparable to Biofarm in product mix, generic-and-supplement positioning, and regional distribution model.
  • Antibiotice Iasi: Romanian pharmaceutical manufacturer producing generics, OTC, and supplements; directly comparable to Biofarm as a same-country peer with overlapping product categories and channel mix.

Regional players

  • Fiterman Pharma: Romanian pharmaceutical and dietary supplement manufacturer with overlapping product categories (OTC and supplements); comparable as a same-geography peer focused on Romanian retail and pharmacy channels.
  • Wörwag Pharma: German-based mid-sized pharmaceutical company with strong CEE commercial presence in generics and supplements, comparable to Biofarm in product positioning and Eastern European go-to-market focus.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Biofarm social profiles

Digital presence

Biofarm financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Biofarm leadership team

Management profile

Number of profiles

Profiles1 record

Biofarm funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Biofarm M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biofarm

What does Biofarm do?

Biofarm is a Romanian pharmaceutical manufacturer founded in 1921 that produces and sells medicines and food supplements. The company manufactures over-the-counter (OTC) medicines and dietary supplements through its own production facilities in Bucharest, distributing its products through pharmacies and retail drug stores in Romania and surrounding markets.

Is Biofarm a public or private company?

Biofarm is a public company. It is classified as public and is currently operating.

When was Biofarm founded?

Biofarm was founded in 1921. It employs 251 to 500 people.

Where is Biofarm based?

Biofarm is headquartered in Bucharest, Romania, in the Europe region.

Who are Biofarm's main competitors?

Broad incumbents on record are STADA Arzneimittel and Polpharma. Direct peers are KRKA, Alvogen, Terapia (Sun Pharma Romania), Gedeon Richter, Zentiva and Antibiotice Iasi. Regional players are Fiterman Pharma and Wörwag Pharma.

Does Biofarm have an API?

No public API is recorded for Biofarm.

What industry is Biofarm in?

Biofarm's product category is Pharmaceutical Manufacturing. Its primary akta.pro industry code is EUAAAIAK, Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
SeeNewsRomania's Biofarm reports weaker H1 resultsRomanian pharmaceutical company Biofarm SA reported weaker financial results for the first half of 2026. The announcement highlights a decline in performance metrics compared to previous periods, reflecting ongoing operational or market challenges for the firm. This report follows the recent acquisition of Biofarm by Poland's Polpharma.Media-outreachPolpharma Strengthens Its Position in Central and Eastern Europe – Biofarm, the Leader of the Romanian Market, Joins the GroupPolpharma Group has completed the acquisition of Biofarm, the Romanian pharmaceutical company, marking a strategic step in its growth plans and strengthening its position in Central and Eastern Europe. Biofarm, founded in 1921, operates two manufacturing facilities and exports products to countries across Europe and Asia, with a portfolio of more than 200 products spanning dozens of therapeutic areas. The acquisition combines Biofarm's strong market position in Romania with Polpharma's regional footprint, creating opportunities to expand product availability and explore additional market presence.NotimericaPolpharma Strengthens Its Position in Central and Eastern Europe – Biofarm Joins the GroupPolpharma Group completed the acquisition of Romanian pharmaceutical company Biofarm, strengthening its position in Central and Eastern Europe. Biofarm, operating since 1921 with two manufacturing facilities and a portfolio of over 200 products, joins the group to expand regional presence and improve patient access to medicines.OTS.atPolpharma Strengthens Its Position in Central and Eastern Europe – Biofarm, the Leader of the Romanian Market, Joins the GroupPolpharma Group completed the acquisition of Romanian pharmaceutical company Biofarm, strengthening its position in Central and Eastern Europe. Biofarm, operating since 1921 with two facilities and a portfolio of over 200 products, will combine with Polpharma to expand regional presence and improve patient access to medicines.Via RitzauPolpharma Strengthens Its Position in Central and Eastern Europe – Biofarm, the Leader of the Romanian Market, Joins the GroupPolpharma Group completed the acquisition of Romanian pharmaceutical company Biofarm, strengthening its position in Central and Eastern Europe. Biofarm, operating since 1921 with over 200 products, joins the group to expand regional presence and improve patient access to medicines.Simply Wall StBiofarm (BVB:BIO)Polpharma SA Pharmaceutical Works proposed to acquire Biofarm S.A. from Longshield Investment Group SA, Lion Capital S.A. and other shareholders for RON 1.4 billion on May 6, 2026, offering RON 1.379 per share in cash, nearly 15% above the market price at the time. Biofarm's shares rose 2.9% on May 7 following the announcement, and the transaction is subject to approval by the Financial Supervisory Authority. A special dividend of RON 0.140263 per share is also intended to be distributed to shareholders before the launch of the voluntary tender offer.Romania InsiderLargest Polish pharma group Polpharma to take over Romania’s Biofarm at EUR 270 mln valuationPoland's largest pharmaceutical group Polpharma has launched a voluntary public takeover offer for Romania's Biofarm at a valuation of approximately EUR 270 million, with the offer price of RON 1.379 per share representing a near 15% premium over the prevailing market price. Romanian investment funds Longshield Investment Group and Lion Capital, which collectively hold 88.4% of Biofarm's shares, have already accepted the offer and committed stakes worth EUR 230 million. Longshield additionally intends to request a special dividend of 0.140263 lei per share ahead of the offer's launch, subject to Financial Supervisory Authority approval.PR NewswireYS BIOPHARMA TO RING THE OPENING BELL AND DEBUT ON NASDAQYS Biopharma completed its business combination with Summit Healthcare and will debut on Nasdaq on March 17, 2023, with ordinary shares and warrants trading under tickers "YS" and "YSBPW". The company, a vaccine and therapeutic biologics developer, will participate in the opening bell ceremony led by CEO Dr. David Hui Shao.Trust & Safety PoliciesIs a 4-Day Workweek Possible for Biopharma?A U.K. pilot program testing a four-day workweek for 3,000 employees and 61 employers concluded with 92% of companies planning to continue. Revenue rose 35% year-over-year, though little changed in company revenue. Biopharma firms remain skeptical due to hands-on lab work, but staggered hours could offer a middle ground.BioWorldBiopharma stocks pull back after rising 17% in 2022BioWorld's Biopharmaceutical Index rose 17.3% in 2022, outperforming the Nasdaq Biotechnology Index and Dow Jones Industrial Average, which fell 10.9% and 8.8% respectively. All three indices followed a similar pattern in 2023, rising in January and declining in recent weeks.